What does this research mean for the field?

Serum CA-125 levels are an independent predictor of long-term mortality in patients with pulmonary arterial hypertension (PAH). Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to assess the prognostic significance of CA-125 levels in patients with pulmonary arterial hypertension (PAH).

March 1, 2026

Cancer antigen-125 is a predictor of mortality in patients with pulmonary arterial hypertension

Resultado clave

CA-125 >35.32 U/ml independently predicted mortality in PAH patients with HR 7.645, 85.7% specificity and 75% sensitivity for death prediction.

Puntos clave

The study aims to assess the prognostic significance of CA-125 levels in patients with pulmonary arterial hypertension (PAH).
Prospective evaluation of 40 consecutive PAH patients.
Comparison of CA-125 levels in survivors vs. non-survivors.
Multivariable analysis using Cox proportional-hazards model to identify predictors of mortality.
30% of patients died during the follow-up period.
CA-125 levels were significantly higher in deceased patients (78.5 vs. 27.5 U/ml, p = 0.001).
Optimal CA-125 cut-off for predicting mortality is 35.29 U/ml, with 85.7% specificity and 75% sensitivity.

PICO estructurado

Does elevated serum CA-125 predict mortality in patients with pulmonary arterial hypertension?

Población

40 consecutive patients with pulmonary arterial hypertension (PAH), mean age 52 +/- 11 years, 12% male, 88% female.

Intervención

Serum CA-125 measurement

Resultado

Long-term mortalityhard clinical

Serum CA-125 levels > 35.32 U/ml on admission serve as an independent predictor of long-term mortality in patients with pulmonary arterial hypertension.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Background: Carbohydrate antigen 125 (CA 125), known as a tumor marker for ovarian cancer, has been reported to increase and be associated with severity in heart failure and chronic obstructive pulmonary disease. Patients with pulmonary arterial hypertension may also die due to developing right heart failure. The aim of this study is to evaluate the prognostic role of CA-125 in PAH patients. Methods: A total of 40 consecutive patients with PAH were evaluated prospectively. The mean age of patients was 52 +/- 11 years (12% males, 88% females) with a median follow-up period of 16 months. Results: After follow-up period, 12 out of 40 patients (30%) died. CA-125 levels were higher among those who died compared to those who survived 78.5 (11.0-292) vs. 27.5 (2.10-138) U/ml, p = 0.001. The optimal cut-off value of CA-125 to predict mortality was found as 35.29 U/ml, with 85.7% specificity and 75% sensitivity. In multivariable Cox proportional-hazards model with forward stepwise method; CA-125 > 35.32 U/ml on admission (HR = 7.645, 95% CI: 1.356-43.121, p = 0.021), age (HR = 1.132, 95% CI: 1.040-1.233, p = 0.004), TAPSE (HR = 0.740, 95% CI: 0.549-0.998, p = 0.048) and uric acid (HR = 1.444, 95% CI: 1.022-2.042, p = 0.037) remained associated with an increased risk of death. Conclusion: In this study, we showed for the first time that serum CA-125 values were an independent predictor for the long-term mortality in PAH patients.

Me gusta

Guardar